Oncotarget

Research Papers:

MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells

Yong Lin, Xin Ge, Yiyang Wen, Zhu-Mei Shi, Qiu-Dan Chen, Min Wang, Ling-Zhi Liu, Bing-Hua Jiang _ and Yuan Lu

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:70857-70868. https://doi.org/10.18632/oncotarget.12268

Metrics: PDF 2116 views  |   HTML 2398 views  |   ?  


Abstract

Yong Lin1,2, Xin Ge3,4, Yiyang Wen3, Zhu-Mei Shi3,5, Qiu-Dan Chen2, Min Wang3, Ling-Zhi Liu6, Bing-Hua Jiang3,6, Yuan Lu1

1Department of Laboratory Medicine, Huashan Hospital of Fudan University, Shanghai, China

2The Department of Clinical Laboratory, Central Laboratory, Jing’an District Centre Hospital of Shanghai, Huashan Hospital of Fudan University Jing’An Branch, Shanghai, China

3State Key Lab of Reproductive Medicine, Key Laboratory of Human Functional Genomics of Jiangsu Province, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention, and Treatment Department of Pathology, Cancer Center, Nanjing Medical University, Nanjing, China

4Ninggao Personalized Medicine and Technology Innovation Center, Nanjing, China

5Department of Neurosurgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

6Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University, Philadelphia, PA, United States of America

Correspondence to:

Bing-Hua Jiang, email: [email protected], [email protected]

Yuan Lu, email: [email protected]

Keywords: pancreatic adenocarcinoma, gemcitabine, miR-145, p70S6K1, chemoresistance

Received: May 09, 2016     Accepted: August 25, 2016     Published: September 27, 2016

ABSTRACT

Pancreatic adenocarcinoma is one of the most leading causes of cancer-related deaths worldwide. Although recent advances provide various treatment options, pancreatic adenocarcinoma has poor prognosis due to its late diagnosis and ineffective therapeutic multimodality. Gemcitabine is the effective first-line drug in pancreatic adenocarcinoma treatment. However, gemcitabine chemoresistance of pancreatic adenocarcinoma cells has been a major obstacle for limiting its treatment effect. Our study found that p70S6K1 plays an important role in gemcitabine chemoresistance. MiR-145 is a tumor suppressor which directly targets p70S6K1 for inhibiting its expression in pancreatic adenocarcinoma, providing new therapeutic scheme. Our findings revealed a new mechanism underlying gemcitabine chemoresistance in pancreatic adenocarcinoma cells.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12268